Join us for a "LIVE" dinner meeting and presentation
Posted about 4 years ago
Topic
Monoclonal antibodies and the Emergency Use Authorization (EUA) to treat COVID-19.
Speaker(s)
Michael McGuire, PharmD, BCPS, Associate Director, Medical Affairs, Regeneron Pharmaceuticals, Inc.
Additional Information
RegenCov is a combination of 2 monoclonal antibodies (casirivimab and imdevimab) that has just received FDA Authorization for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
Register for this event
Seating is limited to DCNP Members only at this time, so please join ~ please only fully vaccinated participants
Per CDC guidelines no masks required for indoor dining if vaccinated